ACE and diabetes mellitus: It fully integrates all major cardiorenal outcomes and studies assessing ACE inhibitors, ARBs, and the DR inhibitor aliskiren in adults with diabetes, thereby providing clinicians and patients with an overall appraisal of these therapies.